| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $3.7M | +3.8% | -24.2% |
| SG&A Expense | $2.1M | +2.7% | -1.2% |
| Operating Income | -$5.9M | -3.3% | +17.2% |
| Income Tax | $0 | — | — |
| Net Income | -$25.4M | -232.4% | -139.8% |
| EPS (Basic) | -$0.68 | -38.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.7M | -11.3% | -28.7% |
| Current Assets | $7.9M | -13.1% | -32.1% |
| Total Assets | $20.4M | -5.7% | -13.0% |
| Current Liabilities | $5.7M | -28.2% | +1.6% |
| Total Liabilities | $47.3M | +64.4% | +197.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.4M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $19.8M | — | — |
| Free Cash Flow | -$17.4M | — | — |
| +76.1% |
| -$26.9M |
| -275.7% |
| -459.9% |